Kainate-induced epilepsy has been shown to be associated with increased levels of neuropeptide Y (NPY) in the rat hippocampus. However, there is no information on how increased levels of this peptide might modulate excitation in kainateinduced epilepsy. In this work, we investigated the modulation of glutamate release by NPY receptors in hippocampal synaptosomes isolated from epileptic rats. In the acute phase of epilepsy, a transient decrease in the efficiency of NPY and selective NPY receptor agonists in inhibiting glutamate release was observed. Moreover, in the chronic epileptic hippocampus, a decrease in the efficiency of NPY and the Y 2 receptor agonist, NPY13-36, was also found. Simultaneously, we observed that the epileptic hippocampus expresses higher levels of NPY, which may account for an increased basal inhibition of glutamate release. Consistently, the blockade of Y 2 receptors increased KCl-evoked glutamate release, and there was an increase in Y 2 receptor mRNA levels 30 days after kainic acid injection, suggesting a basal effect of NPY through Y 2 receptors. Taken together, these results indicate that an increased function of the NPY modulatory system in the epileptic hippocampus may contribute to basal inhibition of glutamate release and control hyperexcitability.
Changes in the expression of various neuropeptides have been observed in different models of temporal lobe epilepsy (Bellmann et al. 1991; Schwarzer et al. 1995) and the hippocampus has attracted particular interest due to its central role in limbic epilepsy (Ben-Ari 1985) . Neuropeptide Y (NPY), a 36 amino acid peptide, is one of the most abundant and widely distributed neuropeptides in the central and peripheral nervous systems. It modulates numerous physiological processes including memory, anxiety, seizures and feeding behaviour (Michel et al. 1998) . Central administration of NPY decreases pharmacologically-and electrically-evoked seizures (Smialowska et al. 1996; Woldbye et al. 1996 Woldbye et al. , 1997 , and transgenic mice lacking endogenous NPY exhibit increased sensitivity to seizure induction (Baraban et al. 1997) . Moreover, the role of endogenous NPY in regulating seizure activity is supported by evidence of increased NPY levels under epileptic conditions in both inhibitory interneurones and in excitatory granule cells that, in control conditions, do not contain the peptide (Vezzani et al. 1999 (Vezzani et al. , 2002 . Park and collaborators (2001) also observed an increase in the number of NPY-positive neurones, and that these neurones are resistant to kainateinduced seizures in the whole hippocampus. More recently, others (Richichi et al. 2004) showed that long-lasting NPY expression in the rat hippocampus, using a recombinant adeno-associated viral vector, reduced electroencephalogram (EEG) seizures and delayed seizure onset markedly.
Seizure-related increase in NPY expression is accompanied by modified levels of NPY receptor subtypes in the hippocampus (Kofler et al. 1997; Gobbi et al. 1998; Schwarzer et al. 1998; Vezzani et al. 2000) , and it seems that more than one receptor subtype could be responsible for mediating the anti-epileptic effects of NPY. This peptide inhibits excitatory neurotransmission and reduces glutamate release by acting mainly on presynaptic Y 2 receptors (Greber et al. 1994; Silva et al. 2001 Silva et al. , 2003a . Indeed, electrophysiological and pharmacological studies have revealed that NPY acts predominantly through Y 2 receptors (Weiser et al. 2000; Silva et al. 2003a ) and inhibits glutamate release by reducing Ca 2+ influx (Schwarzer et al. 1998; Silva et al. 2001 Silva et al. , 2003a . Moreover, the increase in Y 2 receptor binding in the hilus of the dentate gyrus is associated with enhanced release of NPY after kainate injection (Röder et al. 1996) . The involvement of the Y 1 receptor subtype is not so clear, but previous studies have shown that these receptors also inhibit Ca 2+ influx and glutamate release in the dentate gyrus (McQuiston et al. 1996) and CA3 hippocampal subregions, as well as in total hippocampus (Silva et al. , 2003a . The pharmacological profile of centrally administered NPY analogues capable of inhibiting kainate-induced seizures and hippocampal excitability in rats also suggests the involvement, at least in part, of Y 5 receptors (Woldbye et al. 1997; Reibel et al. 2001) . Indeed, using Y 5 R-deficient mice, Marsh et al. (1999) demonstrated that these mice do not exhibit spontaneous seizure-like activity.
Accumulating evidence clearly suggests that seizure activity increases the expression of NPY and NPY receptors. In the present work, we have identified a role for NPY receptors in modulating glutamate release and the variation of NPY levels under epileptic conditions. Moreover, we also suggest that endogenous NPY contributes to basal inhibition of glutamate release in synaptosomes isolated from the epileptic rat hippocampus.
Materials and methods

Kainate treatment
Male 6-week-old Wistar rats (150-200 g) were injected intraperitoneally with kainic acid (KA) (Sigma, St Louis, MO, USA; 10 mg/kg body weight) dissolved in a maximum volume of 500 lL sterile 0.9% NaCl, and a control group of animals were injected with the same volume of saline. Rats were observed for at least 3 h and their behaviour was rated as described previously (Sperk et al. 1983) . All the animals used in the present study achieved status epilepticus and were killed 6 h, 24 h, 72 h and 30 days after KA injection.
All procedures involving experimental animals were performed in accordance with European Community guidelines. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Isolation of rat hippocampal synaptosomes
A partially purified synaptosomal fraction (P 2 ) was isolated from hippocampi or from hippocampal subregions (CA1, CA3 and dentate gyrus-DG) of male Wistar control or epileptic rats (killed 6 h, 24 h, 72 h and 30 days after KA injection), essentially as described previously for brain cortex (McMahon et al. 1992 ) with some modifications (Malva et al. 1996; Silva et al. 2001) . The hippocampi were homogenized in 0.32 M sucrose, 10 mM HEPESNa, pH 7.4, using a Thomas B-Potter homogenizer (Thomas Scientific, Swedesboro, NJ, USA), and centrifuged at 3000 g for 2 min. The pellet obtained was resuspended, followed by sedimentation at the same speed. The combined supernatant fluids were spun for 12 min at 14 600 g and a P 2 pellet was obtained. The upper, whiter layer of the pellet, containing synaptosomes (Whittaker 1984) , was removed with a small spoon and resuspended in the same sucrose medium as that used before.
Coronal slices of hippocampus (800 lm thick) were prepared for the isolation of synaptosomes from hippocampal subregions (CA1, CA3 and DG) of non-epileptic and epileptic rats (24 h and 30 days after KA injection). In each slice, the fimbria and the subiculum were separated from the rest of the slice under stereomicroscopic observation. CA3 subslices were obtained by separation from CA1 and dentate gyrus, and the last separation (CA1 from DG) was performed through the hippocampal sulcus . The pooled subslices were homogenized in the sucrose medium using a Thomas AA-Potter homogenizer, transferred to Eppendorf tubes and centrifuged as described for the isolation of whole hippocampal synaptosomes. The protein concentration was determined by the Biuret method (Layne 1957) for glutamate release experiments, and the synaptosomes were stored as drained pellets containing 1 mg protein. For assessing the NPY content, protein concentration was determined by the bicinchoninic acid (BCA) method (Smith et al. 1985) .
Isolation of total RNA from rat hippocampus Total RNA was isolated from rat hippocampus using TRI REAGENT (Sigma) according to manufacturer's instructions. Briefly, tissue was homogenized in guanidium thiocyanate and phenol. After adding chloroform and centrifuging, the RNA was isolated in the aqueous phase. The RNA was precipitated with isopropanol, the RNA pellet washed with 75% ethanol and the pellet redissolved in diethylpyrocarbonate (DEPC)-treated water.
The total amount of RNA was quantified by optical density (OD) measurements at 260 nm, and the purity was evaluated by measuring the ratio of OD at 260 and 280 nm (RNA/DNA calculator GeneQuant II, Pharmacia Biotech Amersham Biosciences AB, Uppsala, Sweden).
Measurement of glutamate release
The release of endogenous glutamate was followed using a continuous fluorimetric assay as previously described (Nicholls et al. 1987 ) with some modifications (Malva et al. 1996; Silva et al. 2001) . Synaptosomes (1 mg protein) were pre-incubated for 20 min at 37°C in the following medium (in mM): 132 NaCl, , respectively] were added to the incubation medium for an additional 10 min. Synaptosomes were then centrifuged at 15 800 g and resuspended in 1 mL of the same medium but without BSA and with 1 mM CaCl 2 . The suspension was transferred to a stirred acrylic cuvette maintained at 37°C, followed by the addition of 1 mM NADP + , 50 U purified glutamate dehydrogenase and again, NPY receptor agonists or antagonists. Fluorescence was measured using a Perkin Elmer model LS-5B luminescence spectrometer (PerkinElmer Ltd, Beaconfield, Buckinghamshire, UK) at the excitation and emission wavelengths of 340 and 460 nm, respectively, with excitation and emission slits of 5 and 10 nm, respectively. The data were collected at 0.5 s intervals and at the end of each experiment, 2.5 nM L-glutamate were added as a callibration to allow the quantification of released glutamate. Glutamate release was monitored for 11 min and synaptosomes were stimulated 4 min after the beginning of each experiment with 15 mM KCl.
NPY assay
To determine NPY levels in nerve terminals from hippocampal subregions (CA1, CA3 and DG) obtained from control and epileptic rats (killed 24 h and 30 days after KA injection), synaptosomal P 2 pellets were resuspended in 350 lL (CA1) or 200 lL (DG, CA3) of the following medium (in mM): 132 NaCl, 1 KCl, 1 MgCl 2 , 1.2 H 3 PO 4 , 1 CaCl 2 , 10 glucose, 10 HEPES-Na, pH 7.4. The suspension of synaptosomes was then centrifuged at 14 600 g for 12 min at 4°C, and the pellets were frozen at )20°C. Each pellet was resuspended in 250 lL Krebs buffer (50 mM EDTA, 0.08% Tween 20) and 10 lL of this preparation were used to quantify NPY levels. An ELISA system and two antibodies (NPY02 and NPY05) recognizing distinct epitopes of NPY were used as described previously (Grouzmann et al. 1992 ) with some modifications (Cavadas et al. 2001) . This assay measures amidated biologicallyactive NPY. A 96-well plate (Polysorp; Nunc, Naperville, IL, USA) was coated with 200 ng NPY02 diluted in Tris buffer 50 mM, pH 7.5, overnight at 4°C. The plate was washed three times with Tris-Tween buffer (Tris 50 mM, pH 7.5, with 0.08% Tween 20), and 200 lL 5% low-fat milk in Tris-Tween buffer were added for 30 min. The plate was washed four times with Tris-Tween buffer and the NPY standards and samples (100 lL of final volume) were then added overnight at room temperature with slow agitation. Then, after four washes with Tris-Tween buffer, the second antibody, NPY05, conjugated with alkaline phosphatase diluted (1 : 2500) in 5% low-fat milk in Tris-Tween buffer (7 h at room temperature, with slow agitation), was added. After washing twice with Tris buffer containing 0.25% Tween 20 and twice with Tris buffer containing 0.88% NaCl (w/v), 50 lL of substrate (NADPH solution from the ELISA amplification kit; Invitrogen Life Technologies, Carlsbad, CA, USA) was added. After 40 min of incubation, 50 lL of amplifier (ethanol dehydrogenase mixed with diaphorase from the ELISA amplification kit) was added and the OD measured at 492 nm using an ELISA render (spectra II, SLT lab instruments, Salzburg, Austria). The detection limit was 0.25 pM.
RT-PCR analyses NPY Y 2 mRNA expression was determined by reverse transcription-PCR (RT-PCR). First, cDNA was transcribed from 2 lg RNA using avian microblastosis virus (AMV) and an Oligo-p(dT) 15 primer. PCR was performed in a 100 lL reaction system (Roche Molecular Biochemicals, Indianapolis, IN, USA) containing 3 lL template cDNA, 2 lL deoxynucleotide mix, 10 lL 10 · buffer, 2 lL upstream and 2 lL downstream primer, a variable volume of water and 0.5 lLTaq DNA polymerase (35 cycles: at 95°C for 60 s, at 55°C for 60 s and at 72°C for 60 s) (Amersham Biosciences, Amersham, UK). Primers used in PCR reactions were as follows: NPY Y 2 , forward primer 5¢-CTCCAAGCAAATCAGCTTCC-3¢ and the reverse primer 5¢-GTTTTGTGCCTTCGCTGATGG-3¢; b-actin, upstream primer 5¢-GACTACCTCATGAAGATCCT-3¢ and the downstream primer 5¢-ATCTTGATCATGGTGCTG-3¢ (MWG-Biotech AG, Ebersberg, Germany).
PCR products of each sample were subjected to electrophoresis in a 1.5% agarose gel and stained with ethidium bromide. Densitometrical analysis was performed on Versa-Doc Imaging System (Model 3000, Bio-Rad Laboratories, Hercules, CA, USA) and mRNA expression was evaluated by the band-intensity ratio of control versus epileptic rats (% of control).
Statistical analysis
The data are expressed as means ± SEM. Statistics were performed using one-way ANOVA, followed by Dunnett's or Bonferroni's posttests, as indicated in the figure legends.
Results
Characterization of the modulation of glutamate release by NPY receptors in hippocampal synaptosomes obtained from control versus epileptic rats Recently, we showed that NPY (1 lM) inhibited 15 mM KClevoked glutamate release from non-epileptic rat hippocampal synaptosomes (48.2 ± 2.2% of control); total glutamate release in control conditions was 1.1 ± 0.1 nM glutamate/ mg protein/min while in the presence of 1 lM NPY, it was 0.60 ± 0.1 nM glutamate/mg protein/min (Silva et al. 2003a) (Fig. 1a) )-PP, respectively, inhibited glutamate release to 71.6 ± 1.8% (Fig. 1b) , 60.1 ± 2.1% (Fig. 1c ) or 68.2 ± 2.5% (Fig. 1d) , respectively; these inhibitory effects were prevented by selective NPY receptor antagonists (Silva et al. , 2003a . In the present work, we showed that the efficiency of the NPY receptor-mediated inhibition of KClinduced release of glutamate from hippocampal synaptosomes isolated from epileptic rats depends on the stage of the epileptogenic process.
In hippocampal synaptosomes prepared from epileptic rats 6 h after KA injection, the activation of Y 1 receptors with 1 lM [Leu (Fig. 1b) . However, Y 1 receptormediated inhibition of glutamate release was lost 24 h postinjection (97.8 ± 1.8% of control) and at 72 h or 30 days, the inhibitory effect have been recovered (56.9 ± 2.5% and 79.0 ± 2.5% of control) (Fig. 1b) .
The activation of Y 2 receptors with 300 nM NPY 13-36 in synaptosomes obtained from the hippocampus of epileptic rats led to a transient loss of Y 2 receptor-mediated inhibition of glutamate release 6 h post-injection, followed by recovery at 24 h and 72 h post-injection, and again, a loss of Y 2 receptor-mediated inhibition of glutamate release 30 days post-injection. In the presence of 300 nM NPY13-36, KClinduced release of glutamate was 60.1 ± 2.1% in nonepileptic animals and 93.4 ± 3.3%, 68.6 ± 1.4%, 57.2 ± 1.0% or 79.0 ± 3.3% in hippocampal synaptosomes prepared 6 h, 24 h, 72 h or 30 days post-injection with KA (Fig. 1c) . )-PP inhibited glutamate release to 77.4 ± 2.2% of control (Fig. 1d) . However, 24 h after KA injection the efficiency of the Y 5 receptors in inhibiting the release of glutamate decreased (93.0 ± 3.6% of control). The inhibitory modulation of glutamate release in the presence of Y 5 receptor agonist was recovered 72 h and 30 days after KA injection, decreasing to levels above control (55.3 ± 2.3% and 53.0 ± 2.0% of control, respectively) (Fig. 1d) .
Interestingly, the use of the endogenous agonist, NPY (1 lM) (Fig. 1a) , revealed a pharmacological profile very similar to that mediated by the activation of Y 2 receptors alone (Fig. 1c) . In agreement, in rats killed 6 h after KA injection, the inhibitory effect of NPY on glutamate release was abolished (94.1 ± 3.3% of control) but recovered 24 h and 72 h after KA injection (62.0 ± 1.4% and 54.7 ± 2.5% of control) (Fig. 1a) . Thirty days after KA injection the inhibition of glutamate release was again less efficient (71.5 ± 2.5% of control) (Fig. 1a) . All the absolute values of KCl-evoked glutamate release in the presence of the Y 1 , Y 2 , Y 5 receptor agonists or NPY obtained in the previously described experiment are summarized in table 1.
Since NPY and NPY receptors seem to be involved in other factors unrelated to epilepsy, such as stress, we performed some further control experiments. Modulation of glutamate release by NPY13-36 and NPY was observed in synaptosomes obtained from rats injected with saline (0.9% NaCl) and killed 6 h or 24 h after injection. Like in the Fig. 2 Quantitative analysis of the effect of 300 nM NPY13-36 or 1 lM NPY on glutamate release evoked by 15 mM KCl depolarization in hippocampal synaptosomes obtained from rats injected with saline (0.9% NaCl) and killed after 6 h or 24 h. The results represent the mean ± SEM of three to nine independent experiments, in different synaptosomal preparations. **p < 0.01: Bonferroni's post-test, statistical significance when compared with 6 h or 24 h control.
control non-injected rats, we observed that in the presence of 300 nM NPY13-36 (Fig. 2) , glutamate release was inhibited after 6 h or 24 h (62.0 ± 5.9% or 59.2 ± 1.4% of control, respectively), as well as in the presence of 1 lM NPY (Fig. 2) (67.7 ± 2.9% and 62.1 ± 1.7% control, respectively). These results suggest that the loss of inhibition mediated by NPY13-36 or NPY in rats injected with kainate and killed after 6 h is due to the epileptic stage and not to possible stress induced by the injection itself.
Variation of NPY levels in the epileptic hippocampus
The NPY content of synaptosomes prepared from dentate gyrus, CA3 and CA1 hippocampal synaptosomes from control and epileptic rats (killed 24 h and 30 days after KA injection) was determined, as described in Materials and methods. We observed that in non-epileptic animals the NPY content in synaptosomes from the dentate gyrus was higher (271.5 ± 20.4 fM NPY/mg protein) compared with the CA1 and CA3 subregions (144.8 ± 10.9 and 129.3 ± 26.6 fM NPY/mg protein, respectively) (Fig. 3a) . Moreover, we observed that the NPY content in dentate gyrus obtained from epileptic rats killed 24 h after kainate injection increased significantly (444.2 ± 55.1 fM NPY/mg protein) (Fig. 3a) . In the CA1 subregion, the NPY content decreased in epileptic rats (68.4 ± 8.7 fM NPY/mg protein) whereas in the CA3 subregion, the NPY levels remained similar to those observed in the non-epileptic condition (124.4 ± 24.0 fM NPY/mg protein) (Fig. 3a) . However, in synaptosomes obtained from rats killed 30 days after KA injection, we observed increased levels of NPY in all hippocampal subregions (dentate gyrus, 427.1 ± 15.0; CA3, 210.0 ± 10.9 and CA1, 235.3 ± 20.6 fM NPY/mg protein) when compared with the non-epileptic values of the same subregions (138.6 ± 15.0, 76.1 ± 12.4 and 79.3 ± 8.1 fM NPY/mg protein, respectively) (Fig. 3b) .
With regard to the results described above, we observed an increased level of NPY (Fig. 3b) in the chronic epileptic hippocampus but simultaneously, a diminished functional effect of NPY in inhibiting the release of glutamate (Fig. 1d) .
In an attempt to understand these apparent contradictory findings, we decided to investigate a putative basal effect of NPY in inhibiting the KCl-evoked release of glutamate from synaptosomes isolated from the epileptic rat hippocampus. We therefore measured the KCl-evoked release of glutamate in the presence of the Y 1 , Y 2 or Y 5 receptor antagonists (1 lM BIBP3226, 1 lM BIIE0246 or 1 lM L-152 804, respectively). A potentiation of glutamate release was observed only in the presence of the Y 2 receptor antagonist (133.0 ± 3.5% of control) (Fig. 4) . We also performed the same experiments in non-epileptic rats and found that none of the antagonists had an effect by themselves on KClevoked glutamate release (data not shown). Moreover, in agreement with the effect of BIIE0246 (Fig. 4) , we also Fig. 3 NPY levels in synaptosomes isolated from the dentate gyrus (DG), CA1 and CA3 hippocampal subregions obtained from both nonepileptic and epileptic rats killed (a) 24 h or (b) 30 days after KA injection. The results are expressed as mean fM NPY/mg protein ± SEM of two to four independent experiments performed in triplicate. ***p < 0.001: Bonferroni's post-test, statistical significance when compared with non-epileptic rats in the same subregion; #p < 0.05, ##p < 0.01: Bonferroni's post-test, statistical significance when compared with DG from non-epileptic rats; +++ p < 0.001: Bonferroni's posttest, statistical significance when compared with DG from epileptic rats. Neuropeptide Y modulatory system in the epileptic hippocampus 167
observed an increase in Y 2 receptor mRNA levels in the hippocampus of epileptic rats compared with control noninjected animals (827.8% of control) (Figs 5a and b).
Discussion
It is known that NPY receptors modulate the release of glutamate in the hippocampus (Greber et al. 1994; Qian et al. 1997; Whittaker et al. 1999; Silva et al. 2001) and that the inhibition caused by NPY is partially mediated by the activation of the Y 2 receptor subtype, despite the simultaneous presence of Y 1 and Y 5 receptors in the hippocampus (Silva et al. 2003a) . In this study, we demonstrate that in different stages of the epileptogenic process following intraperitoneal injection of rats with KA the ability to modulate the release of glutamate through the activation of NPY receptors is changed. We suggest that in the acute phase of epilepsy (6-24 h post-injection), a transient loss of NPYmediated inhibition of glutamate release may be causally associated with hyperexcitability of the hippocampal neuronal network and seizure activity. Interestingly, following the acute phase (72 h post-injection), an adaptation of the NPYergic modulation of glutamate release was identified and the inhibitory properties of NPY on glutamate release were again close to control levels.
There is considerable evidence suggesting that the plastic changes in NPY receptors (Vezzani et al. 1999 ) and the functional and morphological alterations in peptidergic neurones found in epileptic brain tissue are mediated by glutamate release during seizures. Röder et al. (1996) showed that in the chronic period of epilepsy 7-30 days after KA treatment, NPY Y 2 receptor binding dropped below control except in the hilus of dentate gyrus where it remained elevated. Moreover, following seizures, changes in Y 1 -R mRNA in the hippocampus are widespread but rapid and transient, whereas there is a major increase in Y 2 -R mRNA expression and a rapid and transient increase in Y 5 -R mRNA in the dentate granule cell layer (Kopp et al. 1999) . However, others have suggested a down-regulation of Y 5 receptor in KA-treated rats and kindledrats (Bregola et al. 2000) . The differences that we observed on the modulation of glutamate release by NPY receptor activation could also be due to a variation of protein expression in nerve terminals. We also show that the modulation of glutamate release following activation of the Y 2 receptor subtype is similar to that activated with the endogenous peptide, so it may be expected, as in nonepileptic rats (Silva et al. 2003a) , that NPY inhibits glutamate release by preferentially activating Y 2 receptors rather than Y 1 and Y 5 receptors. Despite the strong evidence associating NPY receptor modulation of glutamate efflux to the epilepsy stage, we should also consider the neurodegenerative processes that occur under such conditions. Borges et al. (2004) recently showed that after pilocarpine-induced status epilepticus in mice, most hilar neurones died and NPY immunoreactivity appeared in the dentate inner molecular layer, indicative of mossy fibre sprouting. Moreover, we have previously shown (Silva et al. 2003b ) that under excitotoxic conditions, the activation of NPY receptors has a neuroprotective effect.
The higher levels of NPY in the dentate gyrus compared with the CA1 and CA3 subregions may result in a higher presynaptic inhibition of glutamate release, probably through the activation of Y 2 receptors. Indeed, we have previously shown that selective Y1, Y 2 or Y 5 receptor activation significantly inhibits glutamate release in rat dentate gyrus (Silva et al. , 2003a . Klapstein and Colmers (1993) showed that NPY inhibited excitatory postsynaptic potentials (EPSPs) evoked in CA1 pyramidal cells from either stratum radiatum or oriens, and also at mossy fibre-CA3, stratum oriens-CA3 and CA3-CA3. By contrast, no inhibitory effect was observed in EPSPs evoked in dentate granule cells from either perforant path or commissural inputs. However, neurochemical studies have already suggested that NPY is abundantly expressed in the dentate gyrus in rodent models of epilepsy and in the epileptic human (Greber et al. 1994; Schwarzer et al. 1998) . Others have shown that NPY inhibits KCl-induced glutamate release in rat dentate gyrus synaptosomes (Whittaker et al. 1999) and in the epileptic human dentate gyrus (Patrylo et al. 1999) . However, as in glutamate release studies, we have also observed different variations in NPY levels depending on the time elapsed after KA injection. At 30 days post-injection, there was an increase in NPY levels not only in the dentate gyrus but also in the CA1 and CA3 subregions, compared with non-epileptic animals. Moreover, Causing et al. (1996) showed an increase in NPY mRNA levels in neurones of the ipsilateral and contralateral dentate gyrus and Ammon's Horn after intermittent excitatory stimulation; NPY mRNA levels peaked at 4-24 h and had returned to baseline by 48 h post-stimulation. Taken together, the results obtained in synaptosomes isolated 30 days after KA injection show that there is a marked decrease in the inhibition of glutamate release due to the activation of Y 2 receptors and a simultaneous increase in NPY levels. These apparently contradictory results were better understood following our observation of a robust increase in the expression of Y 2 receptor mRNA and an increase in KCl-evoked release of glutamate by blocking Y 2 receptors. These results suggest that endogenous NPY inhibits glutamate release through Y 2 receptors under chronic epileptic conditions. Again, a very relevant role for Y 2 receptors in mediating the effects of NPY was identified. In accordance, Röder et al. (1996) showed that the increase in Y 2 receptor binding in the hilus of the dentate gyrus is associated with enhanced NPY release after kainate injection.
In conclusion, our data support the hypothesis that NPY can act as an endogenous neuromodulator that may limit hyperexcitability in a rodent model of epilepsy, since NPY levels and the expression of Y 2 receptor mRNA are upregulated and the modulation of glutamate release through NPY receptors is modified in KA-induced epilepsy. These compensatory changes in the NPYergic system in the epileptic hippocampus may play an important role in the control of pathological excitability. Taken together, these findings may suggest that overexpression of NPY and Y 2 receptors may represent an important adaptation mechanism in the epileptogenic process.
